Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | ACLY | P53396 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | METAP2 | P50579 | 3/20 | 0.42 |
| ▸ | NRP1 | O14786 | 1/20 | 0.42 |
| ▸ | WDR5 | P61964 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2747534 | 0.89 | KCNH2 (0.70) | KCNH2KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL2748477 | 0.83 | KCNH2 (0.53) | KCNH2ACLYKDM4ENRP1WDR5 | |
| SCHEMBL2747281 | 0.74 | KDM1A (0.55) | ACLYKDM4EMEN1CYP3A4KMT2A | |
| SCHEMBL4550972 | 0.73 | KCNH2 (0.54) | KCNH2ACLYKDM4ENRP1WDR5 | |
| SCHEMBL2748212 | 0.72 | KCNH2 (0.70) | KCNH2MEN1KMT2AALDH1A1GAA | |
| SCHEMBL7531342 | 0.71 | ACLY (0.54) | KCNH2ACLYKDM4EMEN1CYP3A4 | |
| SCHEMBL2748631 | 0.70 | KCNH2 (0.60) | KCNH2ACLYKDM4ENRP1MEN1 | |
| SCHEMBL2747676 | 0.70 | PTGDR2 (0.47) | PTGDR2 | |
| SCHEMBL2248038 | 0.69 | ALDH1A1 (0.61) | KCNH2ACLYKDM4EMEN1KMT2A | |
| SCHEMBL1199270 | 0.69 | KCNH2 (1.00) | KCNH2ACLYKDM4ENRP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178699-B2 | Modulators of CCR9 receptor and methods of use thereof | PFIZER INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178699-B2 | Modulators of CCR9 receptor and methods of use thereof | PFIZER INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178699-B2 | Modulators of CCR9 receptor and methods of use thereof | PFIZER INC. (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2220065-A2 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20100029753-A1 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029753-A1 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029753-A1 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2009017719-A2 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009017719-A2 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029753-A1 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | KCNH2 4765/4885ACLY 4546/4885KDM4E 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.